Has Mohammed Munir, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,721 in general payments to Mohammed Munir, MD across 103 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mohammed Munir, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mohammed Munir, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mohammed Munir, MD

Psychiatry · Dedham, MANPI 1881631844

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,955 of the $2,721 with a category attached, or 71.9%. 13 manufacturers reported payments, led by Boehringer Ingelheim at 35.2% of the total. Among psychiatry clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,721in general payments, 2019–2025

Across 103 payments — averaging $26.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim$957
AbbVie$474
Sunovion Pharmaceuticals Inc.$338
Johnson & Johnson$247
Teva Pharmaceuticals USA, Inc.$138
E.r. Squibb & Sons, L.L.C.$122
plus $446 from 7 others

$370,659in research payments, 2019–2025

Across 71 payments — averaging $5220.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$239K
Janssen Research & Development, LLC$94K
Boehringer Ingelheim International GmbH$29K
Teva Pharmaceuticals USA, Inc.$5K
Avanir Pharmaceuticals, Inc.$3K

What the payments were for

Travel & lodging$71926%
Food & beverage$1,95572%
Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim	7	$957
AbbVie(2 entities)	39	$474
Sunovion Pharmaceuticals Inc.	13	$338
Johnson & Johnson	8	$247
Teva Pharmaceuticals USA, Inc.	11	$138
E.r. Squibb & Sons, L.L.C.	1	$122
Otsuka America Pharmaceutical, Inc.	6	$105
Takeda Pharmaceuticals U.S.A., Inc.	7	$100
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	2	$77
Lundbeck LLC	4	$60
Shire North American Group Inc	2	$46
Neuronetics, Inc.	2	$45
Alkermes, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

COBENFY$122
LATUDA$121
SPRAVATO$120

How this compares

$2,721 in reported general payments places this provider in the 90th percentile of 1,431 psychiatry providers in Massachusetts.

See all psychiatry providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$98,616

Medicare patients

412

Services billed

1,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ziprasidone Hcl	14	$1,008
Aripiprazole	26	$810
Lamotrigine	60	$725
Quetiapine Fumarate	44	$663
Sertraline Hcl	50	$611
Duloxetine Hcl	27	$573
Olanzapine	27	$572
Risperidone	18	$526
Mirtazapine	34	$386
Clozapine	13	$331
Quetiapine Fumarate ErQuetiapine Fumarate	13	$307
Buspirone Hcl	44	$281
Clonazepam	25	$201
Prazosin Hcl	23	$192
Bupropion Hcl	16	$189

Paid to pharmacies, not to this prescriber.

Other psychiatry in Dedham

Theresa CerulliNorth Andover$724K
Andrew AldridgeMedford$407K
Amjad BahnassiWorcester$352K
Ximena Sanchez-SamperBoston$258K
Robert AlexanderBelmont$170K
George PapakostasBoston$170K
Xiangyang LiMilford$166K
Ernesto ZilberbergNorth Andover$141K
Maurizio FavaBoston$120K
Craig SurmanCambridge$111K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →